Biossil lays out a concrete path where AI, seasoned biotech talent, and strategic funding converge to accelerate repurposing drugs and delivering them to market.

Clinical progress includes Health Canada approving studies on Senicapoc’s effect on red blood cell breakdown and the FDA granting permission to conduct a confirmatory Rivipansel trial in the U.S., with Canada eyeing conditional approval to bring a 24-hour efficacy window drug to market.

The platform analyzes failed trial data and genomic databases, using graph neural networks to predict drug–target interactions and simulate over 10,000 patient profiles per hour, achieving roughly 85% accuracy in repurposing predictions.

Competition exists with Atomwise and BenevolentAI, but Biossil promotes cost advantages of about 30% and potential regulatory timing benefits through faster orphan-drug approvals in Canada.

Regulatory challenges loom as AI-generated evidence requires acceptance, with potential hybrid models that blend AI insights and traditional validation.

Biossil employs OpenAI language models to read public drug candidate descriptions, converts them into numerical embeddings, and maps these against disease gene data to identify repurposing opportunities.

The company has licensed or purchased 10 molecules, with two in advanced clinical trials and plans to seek conditional approvals to bring three repurposed drugs to market.

Toronto-based Biossil, using the DrugRevive platform, aims to slash the repurposing timeline by 70–80% and speed candidates into trials.

Founded in 2023 by Anthony Mouchantaf and Dr. Alexander Mosa, Biossil targets repurposing failed drugs with AI to uncover new therapeutic potential.

Key partnerships include more than 20 academic and medical institutions across North America and Europe, such as SickKids, Harvard, Mayo Clinic, and Aarhus University.

CEO Mina Nour leads Biossil, which has secured CAD 12 million in seed funding from investors including Golden Ventures, with notable backing from Peter Thiel and OpenAI.

Biossil collaborates with two major pharma companies and benefits from AI expertise linked to Google DeepMind and Pfizer, signaling strong industry interest in AI-driven repurposing.